Compare Solaredge Technologies Inc (SEDG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs TransMedics Group Inc — how do they compare? Solaredge Technologies Inc trades at $32.04 (market cap $2.00B), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and TransMedics Group Inc for 24 Days on average.
| SEDG | TMDX | |
|---|---|---|
Market Cap | $2.00B | $2.74B |
Volume | 2,739,860 | 949,331 |
Sector | Energy | Health |
52-Week High | $78.51 | $150.42 |
52-Week Low | $28.47 | $61.99 |
Typical Hold Time | 34 Days | 24 Days |
Enterprise Value | $1.86B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $31.81, down 4.07% on the day, reflecting ongoing volatility amid a bearish technical signal and mixed earnings. The stock faces fundamental headwinds with a net loss of $405.45 million in 2025 and negative profit margins, though revenue grew to $1.18 billion. Recent news highlights legal investigations and AI data center initiatives, while analyst sentiment remains cautious with a $37.75 consensus target.
The outlook for SEDG is challenged by persistent losses and competitive pressures, but potential upside exists if AI-driven growth targets materialize. Key risks include execution on new initiatives, solar industry financing costs, and legal overhangs. Investors should weigh the high-risk profile against long-term transformation efforts under current market conditions.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
